Epizyme - EPZM Stock Forecast, Price & News

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Epizyme Price Performance

Shares of NASDAQ:EPZM opened at $1.47 on Friday. Epizyme has a one year low of $0.41 and a one year high of $5.80. The business's fifty day moving average price is $1.25 and its 200-day moving average price is $1.12. The stock has a market capitalization of $247.50 million, a PE ratio of -0.85 and a beta of -0.41.

Epizyme (NASDAQ:EPZM - Get Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.15. The business had revenue of $27.53 million for the quarter, compared to analyst estimates of $10.11 million. Epizyme had a negative return on equity of 2,459.33% and a negative net margin of 391.90%. As a group, equities analysts expect that Epizyme will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EPZM has been the topic of several recent research reports. HC Wainwright lowered their price objective on Epizyme from $8.00 to $6.00 and set a "buy" rating on the stock in a research report on Friday, June 3rd. Wedbush cut Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. Cowen cut Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research report on Monday, June 27th. Cowen cut Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research report on Monday, June 27th. Finally, StockNews.com cut Epizyme from a "hold" rating to a "sell" rating in a research report on Monday, August 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $3.00.